BlackRock Inc. Invests $370.19 Million in Prestige Consumer Healthcare Inc. $PBH

Key Points

• BlackRock purchased 7.83 million shares of Prestige Consumer Healthcare in the second quarter, valued at approximately $370.2 million and representing a 16.53% stake. Institutional investors collectively own 99.95% of PBH.
• Prestige Consumer Healthcare exceeded quarterly expectations, reporting $0.98 in earnings per share versus the $0.89 consensus estimate and $265.7 million in revenue, up 6.5% year over year.
• Analyst sentiment remains mixed, with an overall “Hold” rating and a consensus price target of $70.75, while PBH recently traded at $51.38.

BlackRock Inc. purchased a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 7,831,333 shares of the company's stock, valued at approximately $370,187,000. BlackRock Inc. owned approximately 16.53% of Prestige Consumer Healthcare at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Deutsche Bank AG acquired a new stake in Prestige Consumer Healthcare during the 2nd quarter valued at approximately $2,401,000. Rice Hall James & Associates LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $32,602,000. Trust Co. of Vermont acquired a new stake in Prestige Consumer Healthcare in the second quarter worth $399,000. Global Retirement Partners LLC bought a new stake in Prestige Consumer Healthcare in the 2nd quarter valued at about $80,000. Finally, Bank of New York Mellon Corp bought a new position in Prestige Consumer Healthcare in the 2nd quarter worth approximately $15,376,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH opened at $51.38 on Wednesday. The company has a quick ratio of 1.99, a current ratio of 3.23 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $2.43 billion, a price-to-earnings ratio of 14.39, a PEG ratio of 1.63 and a beta of 0.34. The stock's fifty day simple moving average is $49.90 and its 200 day simple moving average is $54.84. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The business had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. During the same period in the prior year, the business posted $0.90 earnings per share. Prestige Consumer Healthcare's revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PBH has been the topic of a number of recent analyst reports. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 14th. Weiss Ratings lowered Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, June 25th. Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a research note on Friday, May 15th. Finally, Zacks Research raised Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a report on Monday, August 10th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source